A real world, multicentre study to investigate the effect of Daclatasvir and Asunaprevir treatment in patients with Heaptitis C virus genotype 1b infection with severe liver fibrosis

Trial Profile

A real world, multicentre study to investigate the effect of Daclatasvir and Asunaprevir treatment in patients with Heaptitis C virus genotype 1b infection with severe liver fibrosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2017 New trial record
    • 04 Mar 2017 Results published in the Journal of Gastroenterology and Hepatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top